CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
Multiple Myeloma Videos
Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma
Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.
Dr. Cho on the Knowledge Deficit in Multiple Myeloma
Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.
Dr. Siegel on Distinguishing Between Classes of Drugs in Myeloma
David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses a trial distinguishing between classes of drugs in myeloma.
Dr. Madduri on Treatment After CAR T Cells in Myeloma
Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.
Dr. Chari Discusses Carfilzomib Dosing in Myeloma
Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.
Dr. Martin on MRD Status in Multiple Myeloma
Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.
Dr. Shah on Initial Results for bb21217 in Multiple Myeloma
Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.
2018 ASH Annual Meeting
Dr. Jagannath on the Importance of Biology in Multiple Myeloma
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.
Evolving Therapy for Myeloma, Initiating Treatment & Risk Stratification
Ajai Chari, MD, defines the landscape of the evolving therapies for myeloma and provides insights into the monitoring of disease progression before initiating therapy and risk stratification.
Advances in the Treatment of Relapsed/Refractory Myeloma
Dr. Parekh on Evolving Treatment Landscape in Myeloma
Samir Parekh, MBBS, associate professor of medicine, Hematology/Oncology, Mount Sinai Hospital, discusses the evolving treatment landscape in myeloma.
Next Page >>
FDA Approval in NSCLC, Priority Review in SCLC, 2018 SABCS Highlights, and More
Jagannath Discusses Building on the Biology of Multiple Myeloma
Real-World irAEs May Be Higher Than Trial Data Indicate
De-Escalation Possible in Curative Setting for HER2+ Breast Cancer
Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.